Volume 11, Issue 4, Pages 592-604 (April 2015) Astrocyte-Derived TGF-β1 Accelerates Disease Progression in ALS Mice by Interfering with the Neuroprotective Functions of Microglia and T Cells  Fumito Endo, Okiru Komine, Noriko Fujimori-Tonou, Masahisa Katsuno, Shijie Jin, Seiji Watanabe, Gen Sobue, Mari Dezawa, Tony Wyss-Coray, Koji Yamanaka  Cell Reports  Volume 11, Issue 4, Pages 592-604 (April 2015) DOI: 10.1016/j.celrep.2015.03.053 Copyright © 2015 The Authors Terms and Conditions

Cell Reports 2015 11, 592-604DOI: (10.1016/j.celrep.2015.03.053) Copyright © 2015 The Authors Terms and Conditions

Figure 1 TGF-β1 Is Upregulated in Astrocytes in the Spinal Cords of Mutant SOD1 Mice and Sporadic ALS Patients (A) Mean mRNA levels of TGF-β isoforms in the lumbar spinal cord of SOD1G93A (2M, 2-month-old; 3.5M, 3.5-month-old; 4M, 4-month-old; and ES, end-stage) mice relative to the ones in 6-month-old non-transgenic (Non-Tg) mice are shown. (B) Mean TGF-β1 mRNA levels in the lumbar spinal cord of end-stage SOD1G85R (G85R) and SOD1G37R (G37R) mice relative to the ones in age-matched Non-Tg mice are shown. (C) Mean mRNA levels of TGF-β1 in SOD1G93A-primary microglia and astrocytes with or without LPS treatment (1 μg/ml) are shown. (A–C) ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Error bars denote SEM (n = 3 in A and C and n = 3–5 in B). (D) Representative images show the ventral horn of the lumbar spinal cord of onset and end-stage SOD1G93A mice stained for TGF-β1 (green), GFAP (red), and Mac-2 (blue), along with the merged image. Magnified images of the outlined areas (white square) also are shown. TGF-β1 expression was elevated in astrocytes (arrowheads) compared with microglia (arrows). Scale bars, 50 μm. (E) Representative images show the ventral horn and the lateral column of the cervical spinal cord in sporadic ALS and control patients stained for TGF-β1 (green), GFAP (red), and DAPI (blue). Note that the signals double-positive for GFAP and TGF-β1 were more prominent in ALS spinal cords than controls. Magnified images of the outlined areas (white square) also are shown. Scale bars, 50 μm. See also Table S1. Cell Reports 2015 11, 592-604DOI: (10.1016/j.celrep.2015.03.053) Copyright © 2015 The Authors Terms and Conditions

Figure 2 Astrocyte-Specific Overproduction of TGF-β1 Accelerates Disease Progression in SOD1G93A Mice (A and B) Immunoblot analysis for TGF-β1 in (A) primary astrocytes isolated from Non-Tg and GFAP-TGF-β1 mice and in (B) the lumbar spinal cords of Non-Tg, 2-month-old (2M), and end-stage (ES) SOD1G93A (G93A) and SOD1G93A/TGF-β1 (G93A/TGF-β1) mice. GAPDH was used as the internal loading control. (C and D) Kaplan-Meier curves for (C) onset and plotted mean onset and (D) survival time and plotted mean survival time for G93A (n = 36), G93A/TGF-β1 (n = 33), and GFAP-TGF-β1 (n = 5) mice are shown. (E) Plotted durations of early (from onset to 10% weight loss) and late (from 10% weight loss to end stage) stages for G93A and G93A/TGF-β1 mice are shown. (F) Weekly mean body weight was plotted for GFAP-TGF-β1 (n = 5), G93A (n = 36), and G93A/TGF-β1 (n = 33) mice. (C–F) ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Mean ± SD were plotted. (G) Rotarod performances were evaluated weekly for GFAP-TGF-β1 (n = 5), G93A (n = 19), and G93A/TGF-β1 (n = 13) mice. Mean holding times on the rotating rod at indicated ages were plotted. (H) Images show toluidine blue-stained axial sections of the L5 ventral root of GFAP-TGF-β1 mice and end-stage G93A and G93A/TGF-β1 mice. Scale bars, 50 μm. (I) The distribution of motor axonal diameters in cross-sections of L5 ventral root of GFAP-TGF-β1 (n = 2), G93A (n = 6), and G93A/TGF-β1 (n = 6) mice were measured and plotted. ∗p < 0.05, ∗∗p < 0.01. Error bars denote SEM. See also Figures S1 and S2. Cell Reports 2015 11, 592-604DOI: (10.1016/j.celrep.2015.03.053) Copyright © 2015 The Authors Terms and Conditions

Figure 3 Quantitative RT-PCR Analyses of Glia/Immune System-Related Molecules in the Lumbar Spinal Cord of SOD1G93A and SOD1G93A/TGF-β1 Mice (A–I) Mean mRNA levels of indicated glia/immune system-related molecules in the lumbar spinal cord of end-stage SOD1G93A (G93A) and SOD1G93A/TGF-β1 (G93A/TGF-β1) mice along with GFAP-TGF-β1 mice relative to the ones from Non-Tg littermates were plotted. Each result was normalized to β-actin. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Error bars denote SEM (n = 3–5). See also Table S2 and Figure S3. Cell Reports 2015 11, 592-604DOI: (10.1016/j.celrep.2015.03.053) Copyright © 2015 The Authors Terms and Conditions

Figure 4 Decreased IGF-I and CD11c Expressions of Deactivated Microglia/Macrophages of SOD1G93A/TGF-β1 Mice (A) Images show the lumbar spinal cord of end-stage SOD1G93A (G93A) and SOD1G93A/TGF-β1 (G93A/TGF-β1) mice stained for Mac-2 (left) and Iba-1 (right). Scale bars, 250 μm. (B and C) Numbers of (B) Mac-2- and (C) Iba-1-positive microglia within the ventral horn area from the lumbar spinal cord of end-stage G93A (blue) and G93A/TGF-β1 (red) mice are shown. ∗p < 0.05. Mean ± SEM were plotted (n = 3). (D) Images show SOD1G93A primary microglia cultured with ACM derived from G93A or G93A/TGF-β1 mice. Scale bars, 50 μm. (E) Mac-2 mRNA levels of SOD1G93A primary microglia cultured in the indicated conditions are shown. ∗∗p < 0.01. Mean ± SEM were plotted (n = 4). (F) Images show the ventral horn of the lumbar spinal cord of G93A (top) and G93A/TGF-β1 (bottom) mice stained for IGF-I, CD68, CD11c, and MHC class II (green) together with Iba-1 (red). Scale bars, 100 μm. (G) Images show the lumbar ventral root of end-stage G93A (left), G93A/TGF-β1 (middle), and Non-Tg (right) mice stained for IGF-I or CD11c (green) and CD68 (red). CD68-positive cells in the ventral root show IGF-I expression (arrowheads). Scale bars, 100 μm. See also Figure S4. Cell Reports 2015 11, 592-604DOI: (10.1016/j.celrep.2015.03.053) Copyright © 2015 The Authors Terms and Conditions

Figure 5 Decreased Number of Infiltrated T Cells and Increased Ratio of IFN-γ/IL-4-Producing T Cells in SOD1G93A/TGF-β1 Mice Flow cytometric analysis of spinal cord lymphocytes from non-transgenic (Non-Tg), end-stage SOD1G93A (G93A), and SOD1G93A/TGF-β1 (G93A/TGF-β1) mice. (A–C) Flow cytometric analyses of (A) CD45hi cells (cells in red-circled areas), (B) CD4/CD8 expression for T cells, and (C) cytokine staining of IL-4 or IFN-γ in T cells are shown. (D) Numbers of each subset of lymphocytes in the spinal cord from each mouse line are shown. (E and F) Numbers of each subset of (E) IFN-γ- or (F) IL-4-producing lymphocytes in the spinal cord from each mouse line are shown. (G) Mean ratios of IFN-γ/IL-4-producing cells are shown. (H) Cell numbers per microliter of CD3+ T cells in the peripheral blood of Non-Tg, GFAP-TGF-β1, end-stage G93A, and G93A/TGF-β1 mice are shown. (D–H) ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. NS, not significant. Mean ± SEM were plotted (n = 6–7 in D–G and n = 8 in H). Cell Reports 2015 11, 592-604DOI: (10.1016/j.celrep.2015.03.053) Copyright © 2015 The Authors Terms and Conditions

Figure 6 Correlation between Decreased Microglial IGF-I/CD11c Expressions and Decreased Number of T Cells with Increased IFN-γ/IL-4 Ratio in the Presence of TGF-β1 Overproduction in Astrocytes Flow cytometric analyses of primary microglia from non-transgenic (Non-Tg), SOD1G93A (G93A), and SOD1G93A/TGF-β1 (G93A/TGF-β1) mice and T cells in PBMC from Non-Tg and end-stage G93A mice in the primary glial and PBMC co-culture assay. (A) Experimental design for the primary glial and PBMC co-culture assay and flow cytometry is shown. (B) Flow cytometric analysis shows IGF-I and CD11c for primary microglia cultured with PBMC (black, Non-Tg; blue, G93A; red, G93A/TGF-β1). (C and D) Plotted relative expression levels of (C) IGF-I and (D) CD11c in primary microglia. Each datum was normalized to that of Non-Tg primary microglia cultured without PBMC. (E) Plotted numbers of each subset of T cells and non-T cells in PBMC from Non-Tg, G93A mice cultured with primary glial cells from each mouse line are shown. (F and G) Plotted numbers of each subset of (F) IFN-γ- and (G) IL-4-producing lymphocyte in PBMC from each mouse line are shown. (H) Plotted mean ratios of IFN-γ/IL-4-producing T cells in PBMC from each mouse line are shown. (C–H) ∗p < 0.05, ∗∗p < 0.01. NS, not significant. Error bars denote SEM (n = 3). (I and J) Plotted Spearman correlations between expression level of (I) IGF-I and (J) CD11c in primary microglia and the ratio of IFN-γ/IL-4-producing T cells in PBMC (n = 9, r = −0.8833, and p = 0.0031 in I and n = 9, r = −0.7833, and p = 0.0172 in J) are shown. See also Figure S5. Cell Reports 2015 11, 592-604DOI: (10.1016/j.celrep.2015.03.053) Copyright © 2015 The Authors Terms and Conditions

Figure 7 Astrocytic TGF-β1 Is a Determinant for Disease Progression and Survival for ALS Mice, and TGF-β Signaling Inhibitor Extends the Survival Time of ALS Mice (A–C) Correlations between survival time, IFN-γ/IL-4 ratio, and TGF-β1 level in SOD1G93A mice. (A) Plotted Spearman correlations (A) between TGF-β1 mRNA and the survival time of SOD1G93A mice (n = 14, r = −0.8194, and p = 0.0003), (B) between ratio of IFN-γ/IL-4 mRNA and the survival time (n = 10, r = −0.8368, and p = 0.0083), and (C) between TGF-β1 mRNA and ratio of IFN-γ/IL-4 mRNA (n = 10, r = 0.7833, and p = 0.0172) are shown. (D–G) Astrocytic TGF-β1 is downregulated in loxSOD1G37R mice with astrocyte-specific deletion of mutant SOD1. (D) A schematic drawing shows astrocyte-specific deletion of mutant SOD1 in loxSOD1G37R mice using Cre-loxP system, which leads to slowing the disease progression. (E) TGF-β1 mRNA levels in the lumbar spinal cord of end-stage loxSOD1G37R/GFAP-Cre– and loxSOD1G37R/GFAP-Cre+ mice relative to age-matched Non-Tg mice are shown. ∗∗p < 0.01. Mean ± SEM were plotted (n = 6). (F) Representative images show the ventral horn of the lumbar spinal cord of end-stage loxSOD1G37R/GFAP-Cre– and loxSOD1G37R/GFAP-Cre+ mice stained for TGF-β1 (green) and GFAP (red), along with the merged image. Scale bars, 50 μm. (G) Mean fluorescent intensities of TGF-β1 in the gray matter of lumbar ventral horn of loxSOD1G37R/GFAP-Cre+ mice relative to loxSOD1G37R/GFAP-Cre– mice. ∗p < 0.05. Error bars denote SEM (n = 3). (H) Peripheral administration of TGF-β inhibitor extended the survival time of SOD1G93A mice. SOD1G93A mice were intraperitoneally injected with SB-431542 (10 mg/kg, n = 8) or vehicle (DMSO/PBS, n = 8) five times per week from 16 weeks old (after disease onset). Kaplan-Meier analysis for the survival time and plotted mean survival showed that SB-431542 extended the survival of SOD1G93A mice (SB-431542: 166.0 ± 8.7 days, vehicle: 156.9 ± 6.3 days, log-rank test: p = 0.0168). ∗p < 0.05. Error bars denote SD (n = 8, four males and four females in each group). See also Figure S6. Cell Reports 2015 11, 592-604DOI: (10.1016/j.celrep.2015.03.053) Copyright © 2015 The Authors Terms and Conditions